The purpose of this study is to determine if SRT to five or fewer OPD sites extends the time patients with advanced ER positive HER2 negative breast cancer are treated with an AI combined with CDK 4/6 inhibitor, i.e. extends the time these patients are treated with the current line systemic therapy. The gene discussed is ESR1; the disease is breast cancer.